In accordance with the Presidential memorandum “Regulatory Freeze Pending Review,” the Drug Enforcement Agency (DEA) and HHS delayed from Feb. 18 to March 21 the effective date of two final rules related to the practice of telemedicine, “Expansion of Buprenorphine Treatment via Telemedicine Encounter” and “Continuity of Care via Telemedicine for Veterans Affairs Patients.” The administration specified the pushback will not impede telemedicine prescribing in the interim, as those covered under the two rules are still permitted to do so under temporary COVID-19 telehealth flexibilities that run through the end of 2025. Public comments on this delay are open through Feb 28.